Looking at TScan Therapeutics, Inc.'s ( NASDAQ:TCRX ) insider transactions over the last year, we can see that ...

智通财经APP获悉，生物技术公司TScan Therapeutics(TCRX.US)周四宣布，将出售约3000万美元的预融资认股权证，能以每股4.00美元的价格购买总计不超过750万股有表决权的股票。截至发稿，该公盘前涨22.68%，报3.57美元。 TCRX已与Lynx1资本管理公司和Lynx1咨询的投资基金签订 ...

智通财经APP获悉，生物技术公司TScan Therapeutics(TCRX.US)周四宣布，将出售约3000万美元的预融资认股权证，能以每股4.00美元的价格购买总计不超过750万 ...

HC Wainwright & Co.：重申TScan Therapeutics(TCRX.US)评级，由买入调整至买入评级, 目标价由15.00美元调整至15.00美元。 TScan Therapeutics（TCRX.US）公司简介 ...

TScan Therapeutics Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company with a market capitalization of $139.57 million, is poised at a critical juncture in its development of innovative ...

TScan Therapeutics, Inc. (TCRX) has been on a downward spiral lately with significant selling pressure. After declining 5.6% over the past four weeks, the stock looks well positioned for a trend ...

The heavy selling pressure might have exhausted for TScan Therapeutics (TCRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall ...

The heavy selling pressure might have exhausted for TScan Therapeutics (TCRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street ...

TScan Therapeutics, Inc. (TCRX) has been on a downward spiral lately with significant selling pressure. After declining 5.6% over the past four weeks, the stock looks well positioned for a trend ...